Findings

What do systematic reviews say?

4,776 questions · 7,311 findings · 959 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,498 · 20.5%GRADE not reported 303 · 4.1%Very low 1,839 · 25.2%Low 1,991 · 27.2%Moderate 1,277 · 17.5%High 403 · 5.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

Sustained virological response · patients on HD with HCV infection

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.56]
1 study · 35 participants
Very low

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

End‐of‐treatment response · patients on HD with HCV infection

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.56]
1 study · 35 participants
Very low

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

Treatment discontinuation · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

Adverse events · patients on HD with HCV infection

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prevention of eclampsia: higher vs lower IV maintenance regimen

Eclampsia · women with pre‐eclampsia

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Prevention of eclampsia: higher vs lower IV maintenance regimen

Eclampsia: 2 g per hour IV maintenance versus 1 g per hour IV maintenance · women with pre‐eclampsia

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 62 participants
Very low

Prevention of eclampsia: higher vs lower IV maintenance regimen

Eclampsia: 2 g per hour IV versus weight‐adjusted maintenance dose · women with pre‐eclampsia

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 86 participants
Very low

Prevention of eclampsia: higher vs lower IV maintenance regimen

Severe morbidity · women with pre‐eclampsia

The review found no eligible studies for this question.

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prevention of eclampsia: higher vs lower IV maintenance regimen

Side effects · women with pre‐eclampsia

Prevention of eclampsia: higher showed no clear difference in side effects compared with lower IV maintenance regimen (low certainty).

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
RR 0.79 [0.61, 1.01]
1 study · 62 participants
Low

Prevention of eclampsia: higher vs lower IV maintenance regimen

Death of baby (up to discharge) · women with pre‐eclampsia

The review found no eligible studies for this question.

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prevention of eclampsia: higher vs lower IV maintenance regimen

Maternal death · women with pre‐eclampsia

The review found no eligible studies for this question.

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prevention of eclampsia: higher vs lower IV maintenance regimen

Other neonatal morbidity · women with pre‐eclampsia

The review found no eligible studies for this question.

1 finding from 1 review

Alternative magnesium sulphate regimens for women with pre‐eclampsia and eclampsia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Improvement in symptoms · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Endoscopic improvement (dichotomous) · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

pH indices ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Improvement in symptoms · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Improvement in pH indices ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Endoscopic metrics ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found